The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Open accessAbstract
Importance: The Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study is an ongoing prevention trial in clinically normal older individuals with evidence of elevated brain amyloid. The large number of participants screened with amyloid positron emission tomography (PET) and standardized assessments provides an unprecedented opportunity to evaluate factors associated with elevated brain amyloid. Objective: To investigate the association of elevated amyloid with demographic and lifestyle factors, apolipoprotein E (APOE), neuropsychological testing, and self- and study partner reports of cognitive function. Design, Setting, and Participants: This cross-sectional study included screening data in the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study collected from April 2014 to December 2017 and classified by amyloid status. Data were was analyzed from 2018 to 2019 across 67 sites in the US, Canada, Australia, and Japan and included 4486 older individuals (age 65-85 years) who were eligible for amyloid PET (clinically normal [Clinical Dementia Rating = 0] and cognitively unimpaired [Mini-Mental State Examination score, ≥25; logical memory IIa 6-18]). Main Outcomes and Measures: Screening demographics, lifestyle variables, APOE genotyping, and cognitive testing (Preclinical Alzheimer Cognitive Composite), self- and study partner reports of high-level daily cognitive function (Cognitive Function Index). Florbetapir amyloid PET imaging was used to classify participants as having elevated amyloid (Aβ+) or not having elevated amyloid (Aβ-). Results: Amyloid PET results were acquired for 4486 participants (mean [SD] age, 71.29 [4.67] years; 2647 women [59%]), with 1323 (29.5%) classified as Aβ+. Aβ+ participants were slightly older than Aβ-, with no observed differences in sex, education, marital or retirement status, or any self-reported lifestyle factors. Aβ+ participants were more likely to have a family history of dementia (3320 Aβ+ [74%] vs 3050 Aβ- [68%]) and at least 1 APOE ε4 allele (2602 Aβ+ [58%] vs 1122 Aβ- [25%]). Aβ+ participants demonstrated worse performance on screening Preclinical Alzheimer Cognitive Composite results and reported higher change scores on the Cognitive Function Index. Conclusions and Relevance: Among a large group of older individuals screening for an Alzheimer disease (AD) prevention trial, elevated brain amyloid was associated with family history and APOE ε4 allele but not with multiple other previously reported risk factors for AD. Elevated amyloid was associated with lower test performance results and increased reports of subtle recent declines in daily cognitive function. These results support the hypothesis that elevated amyloid represents an early stage in the Alzheimer continuum and demonstrate the feasibility of enrolling these high-risk participants in secondary prevention trials aimed at slowing cognitive decline during the preclinical stages of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationJessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014
Self-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760
Self-citationAssociation Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564
(2006) · Annals of Neurology · doi:10.1002/(issn)1531-8249 · Cited by 513
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
Self-citationWard, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., & Arrighi, H. M. (2012) · Neuroepidemiology · doi:10.1159/000334607 · Cited by 349
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30077-7 · Cited by 333
Jack, C. R., Wiste, H. J., Therneau, T. M., Weigand, S. D., Knopman, D. S., Mielke, M. M., Lowe, V. J., Vemuri, P., Machulda, M. M., Schwarz, C. G., et al. (2019) · JAMA · doi:10.1001/jama.2019.7437 · Cited by 324
Meta-analysis of amyloid-cognition relations in cognitively normal older adults
Hedden, T., Oh, H., Younger, A. P., & Patel, T. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828ab35d · Cited by 319
The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals
Sperling, R. A., Mormino, E. C., Schultz, A. P., Betensky, R. A., Papp, K. V., Amariglio, R. E., Hanseeuw, B. J., Buckley, R., Chhatwal, J., Hedden, T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25395 · Cited by 286
Self-citationBuckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.010 · Cited by 276
Self-citationJohnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270
Self-citationDubois, B., Epelbaum, S., Nyasse, F., Bakardjian, H., Gagliardi, G., Uspenskaya, O., Houot, M., Lista, S., Cacciamani, F., Potier, M.-C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30029-2 · Cited by 237
Mixed pathology is more likely in black than white decedents with Alzheimer dementia
Barnes, L. L., Leurgans, S., Aggarwal, N. T., Shah, R. C., Arvanitakis, Z., James, B. D., Buchman, A. S., Bennett, D. A., & Schneider, J. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001834 · Cited by 236
Rabin, J. S., Schultz, A. P., Hedden, T., Viswanathan, A., Marshall, G. A., Kilpatrick, E., Klein, H., Buckley, R. F., Yang, H.-S., Properzi, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1123 · Cited by 221
Self-citationEffect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C., Martins, R. N., Masters, C. L., et al. (2014) · Brain · doi:10.1093/brain/awt286 · Cited by 210
Mormino, E. C., Papp, K. V., Rentz, D. M., Donohue, M. C., Amariglio, R., Quiroz, Y. T., Chhatwal, J., Marshall, G. A., Donovan, N., Jackson, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.018 · Cited by 202
Self-citationAmariglio, R. E., Donohue, M. C., Marshall, G. A., Rentz, D. M., Salmon, D. P., Ferris, S. H., Karantzoulis, S., Aisen, P. S., & Sperling, R. A. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3375 · Cited by 198
Self-citationPetersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196
The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Chen, X., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002914 · Cited by 172
Rabin, J. S., Klein, H., Kirn, D. R., Schultz, A. P., Yang, H., Hampton, O. L., Jiang, S., Buckley, R. F., Viswanathan, A., Hedden, T., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1879 · Cited by 171
Self-citationVemuri, P., Knopman, D. S., Lesnick, T. G., Przybelski, S. A., Mielke, M. M., Graff‐Radford, J., Murray, M. E., Roberts, R. O., Vassilaki, M. E., Lowe, V. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0244 · Cited by 152
Harkins, K. A., Sankar, P. L., Sperling, R. A., Grill, J. D., Green, R. C., Johnson, K. A., Healy, M. E., & Karlawish, J. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0112-7 · Cited by 143
Self-citationATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Soldan, A., Pettigrew, C. A., Fagan, A. M., Schindler, S. E., Moghekar, A., Fowler, C. J., Li, Q.-X., Collins, S. J., Carlsson, C. M., Asthana, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007248 · Cited by 117
Zahodne, L. B., Manly, J. J., Narkhede, A., Griffith, E. Y., DeCarli, C. S., Schupf, N., Mayeux, R. P., & Brickman, A. M. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150530203214 · Cited by 103
Amyloid load in nondemented brains correlates with APOE e4
Caselli, R. J., Walker, D. G., Sue, L. I., Sabbagh, M. N., & Beach, T. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.016 · Cited by 90
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Amariglio, R. E., Buckley, R. F., Mormino, E. C., Marshall, G. A., Johnson, K. A., Rentz, D. M., & Sperling, R. A. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.08.005 · Cited by 80
Self-citationAmyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging
Vemuri, P., Lesnick, T. G., Knopman, D. S., Przybelski, S. A., Reid, R. I., Mielke, M. M., Graff‐Radford, J., Lowe, V. J., Machulda, M. M., Petersen, R. C., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25600 · Cited by 76
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging
Pontecorvo, M. J., Arora, A., Devine, M., Lu, M., Galante, N., Siderowf, A., Devadanam, C., Joshi, A. D., Heun, S. L., Teske, B. F., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3601-4 · Cited by 69
Amyloid pathology in the progression to mild cognitive impairment
Insel, P. S., Hansson, O., Mackin, R. S., Weiner, M. W., & Mattsson, N. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.018 · Cited by 31
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citation
Metadata
- Authors
- Sperling, R. A., Donohue, M. C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K., Siemers, E., Johnson, K. A., Aisen, P. S., & for the A4 Study Team
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-06-01
- Volume
- 77
- Issue
- 6
- Pages
- 735
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W3014487247
- Cited by
- 324
- References
- 36
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.